Latest Content

Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment

May 29th 2025, 9:00pm

By Ryan Scott

Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer.

Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis

May 29th 2025, 8:00pm

By Ryan Scott

Article

A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.

Guiding Light: A Journey of Support and Hope

May 29th 2025, 7:00pm

By Tina M. Mason, PH.D.,APRN, AOCN, AOCNS, FCNS

Article

Christine Simonelli, B.S.N., RN, CCRC, OCN, is amazing, and goes out of her way to help patients and providers.

Tracing a Five-Generation Cancer Legacy Through Genetic Discovery

May 29th 2025, 5:00pm

By Sue McCarthy

Article

I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease myself.

Patritumab Deruxtecan BLA Withdrawn in Non-Small Cell Lung Cancer

May 29th 2025, 4:16pm

By Ryan Scott

Article

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in the U.S. has been withdrawn.

FDA Grants Priority Review to Sevabertinib NDA in HER2+ Lung Cancer

May 29th 2025, 3:00pm

By Spencer Feldman

Article

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer.

Personalizing Prostate Cancer Care With Genetic Testing, PARP Inhibitors

May 29th 2025, 1:00pm

By Kristie L. Kahl

Article

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining treatment with PARP inhibitors.

Expanding Access to Screening May Help Prevent Esophageal Cancer

May 28th 2025, 8:00pm

By Dr. Seper Dezfoli

Video

Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.

HT-KIT Shows Activity in Rare KIT-Driven Cancers, Preclinical Data Finds

May 28th 2025, 7:00pm

By Ryan Scott

Article

Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, including GIST and some leukemias.

Rebuilding Resilience: Navigating Aging and Exercise After CLL

May 28th 2025, 5:00pm

By Andy Winnegar

Article

After running the Boston Marathon at 67, I faced new limits from aging and chronic lymphocytic leukemia — but I’ve found ways to stay strong and resilient.